SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Corixa [CRXA] - cancer vaccines -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (67)3/21/2001 11:39:08 PM
From: Vector1  Read Replies (1) | Respond to of 222
 
Spek, PB and Peter. I agree with all. There were some signs but I was too stubborn to see. I felt that since CRXA purchased the company there was additional due dilligence. What I didn't realize is that CRXA was so weak they had no choice but to roll the dice. I still believe in the molecule but am concerned that the FDA filing is so screwed up they may never get it approved. What a tragedy for those with this disease.

V1



To: Biomaven who wrote (67)3/22/2001 5:04:59 AM
From: Micawber  Respond to of 222
 
So there were indeed some warning signs - the trouble is they were stacked up against very good clinical results.

Probably the hardest part in walking the biotech minefield, especially in the current market condition. Wasn't the large short interest a clue that I ignored, too?


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News